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Summary
Background  and  objective:  Deterioration  of  nutritional  status  during  PEG-interferon  containing
therapy for  chronic  hepatitis  C  can  be  ameliorated  by  preventive  nutritional  support.  We  aimed
to explore  whether  such  support  also  affects  paid  labour  productivity,  physical  exercise  and
performance  status.
 This study was registered at ClinicalTrials.gov (identifier NCT00841243).
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Methods:  In  this  prospective  randomized  controlled  trial  (J  Hepatol  2012;57:1069—75),  53
patients with  chronic  hepatitis  C  had  been  allocated  to  ‘‘on  demand’’  support  (n  =  26:  nutri-
tional intervention  if  weight  loss  >  5%)  or  preventive  support  (n  =  27:  regular  dietary  advice  plus
energy- and  protein-rich  evening  snack)  during  PEG-interferon-containing  therapy.  Paid  labour
productivity,  physical  exercise  and  performance  status  were  evaluated  at  baseline,  after  24  and
(if applicable)  after  48  weeks  of  treatment.
Results:  At  baseline,  46%  of  patients  performed  paid  labour  and  62%  performed  some  kind  of
physical exercise.  Furthermore,  most  patients  were  able  to  carry  out  normal  activity  with  only
minor symptoms  of  disease  (mean  Karnofsky  performance  score:  94).  Decreases  of  paid  labour
productivity  (—21%  vs.  —70%,  P  =  0.003),  physical  exercise  activity  (—43%  vs.  —87%,  P  =  0.005)
and Karnofsky  performance  scores  (—12%  vs.  —24%,  P  <  0.001)  were  less  in  the  preventive  than
in ‘‘on  demand’’  group  after  24  weeks  of  treatment.  Effects  of  preventive  nutritional  support
were even  more  pronounced  after  48  weeks.
Conclusions:  Preventive  nutritional  support  markedly  ameliorates  decreases  of  paid  labour  pro-
ductivity, physical  exercise  and  performance  status  during  PEG-interferon-containing  treatment
for chronic  hepatitis  C.


































































hronic  hepatitis  C  (CHC)  is  a  leading  cause  of  liver  cirrhosis
orldwide.  Antiviral  therapy  for  CHC  has  changed  strongly
ver  the  past  few  decades  and  is  nowadays  highly  effec-
ive.  Until  2012,  combined  pegylated  (PEG)-interferon  plus
ibavirin  was  the  standard  of  care  for  CHC  and  resulted  in  a
ustained  virological  response  (SVR)  in  40—90%  of  treatment-
aïve  patients  [1—4].  Nevertheless,  interferon  containing
ntiviral  therapy  is  associated  with  significant  side  effects,
hich  may  affect  paid  labour  productivity,  physical  exercise
ctivity  and  performance  status.
Significant  weight  loss  during  interferon-containing
ntiviral  therapy  often  occurs  because  of  decreased
ppetite  due  to  fatigue,  fever,  nausea,  depression  or
aste  changes  during  antiviral  treatment  [5]. Furthermore,
nterferon--based  therapy  delays  gastric  emptying,  which
ould  lead  to  upper  abdominal  discomfort  and  less  appetite
6].  Average  weight  loss  during  treatment  is  reported  to
e  approximately  7%  of  basal  weight  [5,7,8].  Weight  loss
ay  be  even  more  pronounced  with  triple  therapy  con-
aining  protease  inhibitors  [9].  Severe  weight  loss  during
ntiviral  therapy  is  accompanied  by  a  catabolic  state  and
rotein—energy  malnutrition,  which  is  also  a  frequent  phe-
omenon  in  advanced  hepatic  disease  [10].  A  late-evening
rotein-rich  nutritional  supplement  induces  an  anabolic
tate  in  patients  with  advanced  liver  disease  [11]. In  a
ecently  published  randomized  controlled  trial  (RCT)  [7],
e  found  that  preventive  nutritional  advice  plus  an  energy-
nd  protein-rich  evening  snack  before  bedtime  also  pre-
ents  deterioration  of  nutritional  status  of  patients  during
EG-interferon-containing  antiviral  treatment  for  CHC,  with
mproved  digestive  symptoms  and  quality  of  life.  Of  note,
uch  nutritional  support  also  prevents  catabolic  state,  as
ndicated  by  preserved  handgrip  strength  according  to  Jamar
12—14],  pinch  grip  strength  and  other  parameters  of  nutri-




In  previous  studies,  presence  of  CHC  was  associated  with
ess  work  productivity  and  more  absenteeism  [15].  These
ndings  were  even  more  pronounced  during  PEG-interferon-
ontaining  therapy  [16—19].
In  the  current  study,  we  examine  the  effects  of
reventive  versus  ‘‘on-demand’’  nutritional  advice  plus
upplementation  on  paid  labour  productivity,  physical
xercise  and  performance  status  during  PEG-interferon-
ontaining  treatment  for  CHC.
atients and methods
atient  and  clinical  characteristics
n  a  previously  published  RCT  performed  in  the  period
008—2010,  we  evaluated  potential  beneficial  effects
f  preventive  nutritional  support  during  PEG-interferon-
ontaining  antiviral  treatment  for  CHC  on  nutritional  state
nd  quality  of  life  [7].  Nevertheless,  no  data  on  paid  labour
roductivity,  physical  exercise  or  performance  status  have
een  included  in  this  previous  publication.  We  therefore
nalyzed  data  on  effects  of  preventive  nutritional  support
n  paid  labour  activity,  physical  exercise  and  performance
tatus.  These  data  had  been  prospectively  collected  and
ere  all  available  in  the  database  of  this  RCT.  In  total,  53
atients  tested  positive  for  serum  hepatitis  C  virus  (HCV)-
ntibodies  and  HCV  RNA  during  at  least  6  months  and  with
n  indication  for  antiviral  treatment  [20—22]  were  random-
zed  for  the  ‘‘on  demand’’  group  (n  =  27)  or  the  preventive
roup  (n  =  26).  Both  groups  received  PEG-interferon  alfa-
b  1.5  g/kg/week  subcutaneously  and  oral  ribavirin  for  24
r  48  weeks  depending  on  genotype  and  viral  load.  Ribavi-
in  dose  was  800,  1000,  1200,  and  1400  mg/day  for  body
eight  <  65  kg,  65—75  kg,  76—105  kg,  and  >  105  kg,  respec-ively.  Duration  of  antiviral  therapy  was  29  ±  14  weeks  in
he  ‘‘on  demand’’  and  32  ±  12  weeks  in  the  preventive  group















































Nutritional  support  and  anti-HCV  therapy  
and  1.41  ±  0.3  g/kg/week)  and  ribavirin  dosage  (13.9  ±  1.6
and  14.5  ±  2.1  mg/kg/day)  did  not  differ  between  both
groups  [7].  In  the  preventive  group,  patients  received
dietary  advice  from  a  specialized  nutritionist  during  their
regular  visits  as  well  as  an  energy-  and  protein-rich  evening
snack  to  be  taken  daily  before  bedtime.  Dietary  advice
included  frequent  energy  and  protein  enriched  meals  with
a  high  ratio  of  protein  versus  carbohydrates  during  the  day.
The  prescribed  Nutridrink  protein® (Nutricia,  Zoetermeer,
The  Netherlands)  contains  20  g  protein,  300  kcal  and  25%  of
the  advised  daily  amounts  of  all  other  essential  nutrients.
Only  in  case  of  significant  (>  5%  of  baseline)  weight  loss,
patients  in  the  ‘‘on  demand’’  group  received  dietary  advice
and  supplementation.  The  study  was  conducted  accord-
ing  to  recommendations  of  Good  Clinical  Practice  and  the
Declaration  of  Helsinki.  Written  informed  consent  was  pro-
vided  by  all  patients  and  the  protocol  was  approved  by
the  medical  ethical  committees  of  all  participating  centres.
This  study  was  registered  at  ClinicalTrials.gov  (identifier
NCT00841243).
Paid  labour  productivity
For  the  assessment  of  paid  labour  productivity,  we  asked
the  patients  to  provide  us  with  their  productivity  status  at
baseline  and  at  the  endpoint  of  24  weeks  and,  if  applica-
ble,  48  weeks  of  treatment.  Paid  labour  productivity  was
defined  as  paid  full  time  or  part  time  white  collar  (physically
inactive)  labour,  blue  collar  (physically  active)  labour  or
none.  Loss  of  paid  labour  productivity  was  based  on  percent-
age  of  baseline  productivity  at  24  weeks  and,  if  applicable,
48  weeks  of  treatment,  in  only  those  patients  who  had  any
kind  of  paid  labour  productivity  at  baseline  and  separately
for  the  total  group  (those  with  as  well  as  those  without  paid
labour  activity  at  baseline).  In  addition,  unpaid  household
activities  were  assessed  in  all  patients  without  paid  labour
productivity  at  baseline.
Physical  exercise
For  the  assessment  of  physical  exercise  (outside  paid  labour
working  hours),  we  asked  the  patients  to  provide  us  with
their  weekly  physical  exercise  activity  at  baseline  and  at  the
endpoint  of  24  weeks  and,  if  applicable,  48  weeks  of  treat-
ment.  Patients  were  divided  into  the  following  subgroups
according  to  their  physical  exercise  activity  per  week:
•  none;
•  60  to  150  minutes  of  low  intensity  exercise;
•  >  150  minutes  of  low  intensity  exercise;
•  60  to  150  minutes  of  high  intensity  exercise;
•  >  150  minutes  of  high  intensity  exercise.
Low  intensity  exercise  was  defined  as  walking  and  leisure
cycling.  High  intensity  exercise  was  defined  as  strength
training,  running  and  intense  cycling.  Loss  of  physical  exer-
cise  was  defined  as  percentage  of  baseline  physical  exercise
activity  at  24  weeks  and,  if  applicable,  48  weeks  of  treat-
ment,  in  only  those  patients  with  any  level  of  physical








he  Karnofsky  performance  status  (KPS)  scale,  which  ranges
rom  0—100,  was  used  to  evaluate  performance  status  out-
omes  of  patients  at  baseline,  at  24  weeks  and,  if  applicable,
8  weeks  of  antiviral  treatment  [23].
tatistical  analysis
ontinuous  data  are  given  as  means  and  standard  deviations
SD)  or,  in  case  of  a non-parametric  distribution,  as  medians
nd  ranges,  and  discrete  variables  as  absolute  and  relative
requencies.  Differences  between  the  ‘‘on  demand’’  and
reventive  groups  were  tested  for  statistical  significance  by
ndependent  t-test,  Mann—Whitney  U-test  or  Pearson  Chi2
est,  as  appropriate.  Pair-samples  t-test  was  used  to  com-
are  differences  between  time  points  in  the  same  group.  A
wo-sided  P-value  <  0.05  was  considered  statistically  signif-
cant.  Statistical  analysis  was  performed  using  SPSS  version
1.0  for  Windows.
esults
atient  and  clinical  characteristics
aseline  characteristics  of  all  53  patients  who  were  random-
zed  for  the  ‘‘on  demand’’  group  (n  =  27)  or  the  preventive
roup  (n  =  26),  and  separately  for  those  who  reached  the  pri-
ary  endpoint  of  24  weeks  of  antiviral  treatment  (n  =  22  in
oth  groups)  are  given  in  Table  1.  Mean  age  was  49  years
nd  majority  of  patients  was  male  (72%).  Furthermore,  87%
f  patients  were  treatment-naïve  and  half  of  patients  (53%)
ad  only  mild  liver  disease  (F0—2).  In  the  patients  who  were
reated  for  at  least  24  weeks  (n  =  22  in  both  groups),  there
ere  no  significant  differences  in  baseline  host  or  viral  char-
cteristics  between  both  treatment  arms,  except  a  higher
roportion  of  co-morbidity  in  the  preventive  group  (Table  1).
ffects  of  preventive  nutritional  support  during
ntiviral treatment  on  paid  labour  productivity
t  baseline,  paid  labour  was  performed  by  24  of  the  53
atients  (46%):  15%  performed  full  time  white  collar  labour,
9%  full  time  blue  collar  labour,  6%  part  time  white  col-
ar  labour  and  6%  part  time  blue  collar  labour.  There
ere  no  significant  differences  in  paid  labour  productivity
etween  the  ‘‘on  demand’’  and  preventive  groups  (Table  1).
f  the  patients  without  paid  labour  productivity  at  base-
ine  (n  =  29),  13  patients  (45%)  performed  unpaid  household
ctivities.
Data  on  paid  labour  productivity  during  antiviral  therapy
re  given  in  Fig.  1A  and  B.  After  24  weeks  of  treatment,  paid
abour  productivity  decreased  in  both  groups,  but  loss  of
aid  labour  productivity  was  significantly  larger  in  the  ‘‘on
emand’’  group  (—70%)  than  in  the  preventive  group  (—21%)
P  =  0.003)  (Fig.  1A  and  B),  based  on  only  those  patients  with
ny  paid  labour  at  baseline  (n  =  22).  After  48  weeks  of  treat-
ent  this  difference  was  even  greater:  —89%  in  the  ‘‘on
emand’’  group  vs.  —17%  in  the  preventive  group  (P  =  0.023)
Fig.  1A  and  1B).  When  the  total  group  (n  =  44)  was  taken
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Table  1  Baseline  characteristics  of  53  chronic  hepatitis  C  patients  and  separately  for  the  patients  with  ‘‘on  demand’’  nutritional
support (n  =  22)  or  preventive  nutritional  support  (n  =  22)  who  continued  antiviral  therapy  during  at  least  24  weeks.
All  patients
(n =  53)
‘‘On  demand’’  group
(n  =  22)
Preventive  group
(n  =  22)
P-valueb
Age  (years),  mean  (SD)  49  ±  11  51  ±  9  45  ±  11  0.063
Male sex,  n  (%)  38  (72)  15  (68)  17  (77)  0.498
Weight (kg),  median  (range) 80  (46—105) 78  (69—83)  79  (69—81)  0.841
BMI (kg/m2),  mean  (SD) 25.9  ±  4.0 25.5  ±  4.3 24.9  ±  3.4  0.751
HCV genotype,  n  (%) 0.365
1 or  4 30  (57) 10  (45) 13  (59)
Other 23  (43)  12  (55)  9  (41)
Naïve, n  (%)  46  (87)  20  (91)  19  (86)  0.635
Liver disease,  n  (%)  0.761
F0—2 28  (53)  12  (55)  13  (59)
F3—4 24 (45) 10  (45) 9  (41)
Missing data 1  (2) 0  (0) 0  (0)
Co-morbidity,  n  (%) 20  (38) 4  (18) 11  (50) 0.026
Cause of  disease,  n  (%)  0.082
IV drug  use  13  (25)  8  (36)  3  (14)
Other 40  (75)  14  (64)  19  (86)
Baseline viremia,  n  (%)  0.353
Low viral  load  (<  400,000  IU/mL)  25  (47)  12  (55)  15  (68)
High viral  load  (>  400,000  IU/mL)  28  (53)  10  (45)  7  (32)
Routine blood  tests,  median  (range)
AST  (U/L)  54  (13—241)  54  (48—105)  70  (52—95)  0.808
ALT (U/L)  86  (29—417)  106  (81—169)  84  (74—127)  0.552
Alkaline phosphatase  (U/L)  81  (25—156)  86  (73—94)  77  (68—97)  0.974
Albumin (g/L)  41.2  (30.7—48.0)  41.2  (39.1—42.7)  40.5  (38.7—42.2)  0.715
GT (U/L)  43  (15—371)  38  (30—76)  53  (29—127)  0.742
Bilirubin (mol/L)  16  (4—29)  14  (13—19)  16  (13—21)  0.783
INR 1.02  (0.95—1.48)  1.02  (1.01—1.08)  1.04  (1.02—1.17)  0.359
PTT (s)  13.7  (9.9-17.9)  13.7  (12.7-14.1)  13.7  (12.5-14.6)  0.977
Creatinine (mol/L)  75  (41—106)  72  (65—76)  75  (62—84)  0.172
Haemoglobin  (mmol/L)  9.1  (7.4—10.6)  8.9  (8.5—9.4)  9.3  (9.0—9.8)  0.307
TSH (mlU/L)  1.2  (0.6—3.9)  1.1  (1.1—2.1)  1.6  (1.2—2.3)  0.759
Thrombocytes  (×109/L)  200  (43—371)  206  (179—236)  212  (170—257)  0.867
Paid labour  productivity,  n  (%)  0.579
None 29  (54)  11  (50)  11  (50)
Full time  white  collar 8  (15) 3  (14)  4  (18)
Full time  blue  collar  10  (19)  6  (27)  4  (18)
Part time  white  collar  3  (6)  0  (0)  2  (9)
Part time  blue  collar  3  (6)  2  (9)  1  (5)
Unpaid household  activitiesa,  n  (%) n  =  29  n  =  11  n  =  11  0.193
Yes 13  (45)  6  (55)  3  (27)
None 16  (55)  5  (45)  8  (73)
Physical exercise,  n  (%)  0.953
None 20  (38)  6  (27)  8  (36)
Low intensity,  60—150  min/week  5  (9)  2  (9)  2  (9)
Low intensity,  >150  min/week  16  (30)  7  (32)  7  (32)
High intensity,  60—150  min/week  2  (4)  1  (5)  1  (5)
High intensity,  >  150  min/week  10  (19)  6  (27)  4  (18)
KPS score,  mean  (SD)  94  (9)  94  (10)  94  (8)  0.913
Data are presented as n (%), mean ± SD and/or median (range). All routine blood tests are presented as median (range); KPS: Karnofsky
performance status.
a In only those patients without paid labour productivity at baseline (n = 29).
b P-value applies to differences between the ‘‘on demand’’ and preventive groups.
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Figure  1  Paid  labour  productivity  as  percentage  of  baseline  in  patients  with  chronic  hepatitis  C  with  ‘‘on  demand’’  nutritional
support (a)  or  preventive  nutritional  support  (b)  at  24  and  (if  applicable)  48  weeks  of  antiviral  treatment  (n  =  11  in  both  groups,
only patients  with  any  paid  labour  activity  at  baseline  included).  Preventive  nutritional  support  significantly  decreases  loss  of  paid



























lines, bars  indicate  means  with  standard  deviations.  For  clarity
below zero  and  error  bars  positioned  upward.
into  account  regardless  of  paid  labour  productivity  at  base-
line,  mean  paid  labour  productivity  changed  with  —35%  vs.
—6%  after  24  weeks  of  treatment  (P  =  0.018)  and  with  —8%
vs.  0%  after  48  weeks  of  treatment  in  the  ‘‘on  demand’’  and
preventive  groups,  respectively  (P  =  0.079).
Of  the  six  patients  with  only  unpaid  household  activities
at  baseline  in  the  ‘‘on  demand’’  group,  only  one  contin-
ued  performing  unpaid  household  activities  during  the  first
24  weeks  of  treatment.  After  48  weeks,  all  three  patients  in
the  ‘‘on  demand’’  group  stopped  performing  unpaid  house-
hold  activities.  In  contrast,  in  the  preventive  group,  two  of
the  three  patients  with  only  unpaid  household  activities  at
baseline  continued  performing  unpaid  household  activities
and  the  third  patient  even  had  started  full  time  white  col-
lar  paid  labour  during  the  first  24  weeks  of  treatment.  After
48  weeks  two  of  these  patients  still  performed  part  time
white  collar  labour  or  unpaid  household  activities,  respec-
tively.
Effects  of  preventive  nutritional  support  during
antiviral treatment  on  physical  exercise
At  baseline,  many  patients  (38%)  performed  no  physical
exercise  at  all,  9%  had  60  to  150  minutes  of  low  intensity
exercise  per  week,  30%  had  >  150  minutes  of  low  intensity
exercise  per  week,  4%  had  60  to  150  minutes  of  high  intensity
exercise  per  week  and  19%  had  >  150  minutes  of  high  inten-
sity  exercise  per  week  (Table  1).  In  patients  who  received
at  least  24  weeks  of  treatment  no  significant  differences  in
baseline  physical  exercise  activity  were  found  between  the





e  individual  points  at  baseline  are  depicted  slightly  above  or
hysical  exercise  decreased  after  24  and  48  weeks  of  treat-
ent  in  both  groups.  Nevertheless,  in  the  preventive  group,
his  reduction  was  significantly  smaller  than  in  the  ‘‘on
emand’’  group.  At  24  weeks  of  antiviral  therapy,  physical
xercise  had  decreased  with  87%  in  the  ‘‘on  demand’’  group
nd  with  43%  in  the  preventive  group  (P  =  0.005)  (Fig.  2A  and
).  In  the  subgroup  of  patients  with  48  weeks  of  therapy,
ecrease  of  physical  exercise  at  48  weeks  was  90%  in  the  ‘‘on
emand’’  group  and  0%  in  the  preventive  group  (P  = 0.027)
Fig.  2A  and  2B).  These  decreases  were  calculated  based
n  only  those  patients  with  any  physical  exercise  activity
t  baseline  (n  =  30).  When  the  total  group  (n  =  44)  was  taken
nto  account  regardless  of  physical  activity  at  baseline,  phys-
cal  exercise  was  decreased  with  64%  and  25%  at  24  weeks
f  treatment  (P  =  0.001)  and  with  64%  and  9%  at  48  weeks  of
reatment  (P  = 0.090)  in  the  ‘‘on  demand’’  and  preventive
roups,  respectively.
ffects  of  preventive  nutritional  support  during
ntiviral treatment  on  performance  status
t  baseline,  there  were  no  significant  differences  in  per-
ormance  status  between  patients  in  those  ‘‘on  demand’’
nd  preventive  groups  who  received  at  least  24  weeks
f  treatment.  Mean  KPS  score  was  94  ±  10  in  the  ‘‘on
emand’’  group  and  94  ±  8  in  the  preventive  group,  indi-
ating  that  most  patients  were  able  to  carry  out  normal
ctivity  with  only  minor  symptoms  of  disease  (Table  1).  After
4  weeks  of  treatment,  performance  status  decreased  in
oth  groups,  but  this  decrease  was  significantly  higher  in
he  ‘‘on  demand  group’’  (—24%)  than  in  the  preventive  group
226  E.J.  Huisman  et  al.
Figure  2  Physical  exercise  as  percentage  of  baseline  in  patients  with  chronic  hepatitis  C  with  ‘‘on  demand’’  nutritional  support
(a) or  preventive  nutritional  support  (b)  at  24  and  (if  applicable)  48  weeks  of  antiviral  treatment  (n  =  16  and  14  ‘‘on  demand’’
and preventive  groups,  only  patients  with  any  physical  activity  at  baseline  included).  Preventive  nutritional  support  significantly
























































onnected with  lines,  bars  indicate  means  with  standard  devia
lightly above  or  below  zero  and  error  bars  positioned  upward.
—12%)  (P  <  0.001).  Similar  results  were  found  after  48  weeks
f  treatment  (decrease  of  28%  in  the  ‘‘on  demand’’  group
nd  of  15%  in  the  preventive  group,  P  =  0.017).
iscussion
resence  of  CHC  is  associated  with  significant  impact  on
aid  labour  productivity,  physical  exercise  and  performance
tatus  with  further  deterioration  during  PEG-interferon-
ontaining  therapy,  as  underscored  in  the  current  work.  A
ajor  finding  of  our  study  is  that  preventive  nutritional
dvice  plus  supplementation  decreases  such  loss  of  paid
abour  productivity,  physical  exercise  activity  and  perfor-
ance  status  during  antiviral  therapy  for  CHC.  Interestingly,
nother  study  previously  reported  that  acetyl-l-carnitine
upplementation  during  PEG-interferon-containing  anti-CHC
herapy  decreases  fatigue  and  increases  quality  of  life  [24].
ecently,  it  was  suggested  that  acetyl-l-carnitine  supple-
entation  also  reduces  loss  of  work  productivity  during
nti-CHC  therapy  [25].
Several  studies  have  investigated  the  impact  of  CHC
nfection  on  work  impairment  in  a  large  number  of  partic-
pants  [15,19,26—30].  Similar  to  our  findings,  proportion  of
HC  patients  being  unemployed  in  absence  of  antiviral  ther-
py  was  high  in  these  studies  (range:  7—74%).  Furthermore,
HC-infected  workers  reported  higher  levels  of  overall  workmpairment  than  controls  [15,19,26—30]. Other  studies  eval-
ated  the  effect  of  anti-CHC  therapy  on  work  impairment.  In
ine  with  our  results,  work  productivity  decreased  strongly





s.  For  clarity,  some  individual  points  at  baseline  are  depicted
uring  anti-CHC  treatment,  patients  reported  more  absence
ays  and  lower  productivity  compared  to  baseline  or
ntreated  CHC  patients  [15—17,31,32]. For  example,  Aggar-
al  et  al.  reported  a  mean  increase  in  number  of  absence
ays  of  3  days  compared  to  baseline  during  the  previous
onth  after  12  weeks  of  anti-CHC  therapy.  Furthermore
ore  than  50%  of  patients  reported  decreased  productivity
17]. Brook  et  al.  [16]  reported  lower  numbers:  CHC-
mployees  who  received  antiviral  treatment  had  0.52  more
ealth-related  work  absence  days  than  non-treated  CHC-
mployees,  missing  an  average  of  1.27  workdays  monthly.
urthermore,  treated  CHC  employees  had  12%  fewer  units
rocessed  per  hour  worked  than  those  without  treatment,
ut  this  difference  was  not  statistically  significant  [16].  On
he  other  hand,  reaching  SVR  resulted  in  improvement  of
aid  labour  productivity  with  less  absenteeism  than  in  non-
esponders  [15,31,33]. Previous  studies  also  demonstrated
hat  CHC-patients  in  general  perform  less  physical  exer-
ise  than  non-CHC  subjects  [28,30].  In  our  study,  proportion
f  patients  who  performed  no  physical  exercise  at  base-
ine  was  38%.  During  antiviral  therapy,  physical  exercise  and
arnofsky  performance  status  decreased  strongly  in  patients
ithout  preventive  nutritional  support.  These  findings  are  in
ine  with  other  studies  reporting  a  decrease  in  the  physical
omponent  score  of  the  SF-36  quality  of  life  questionnaire
uring  interferon-containing  treatment  for  CHC  [31,32].
In  general,  productivity  is  defined  as  an  overall  measure
f  the  ratio  of  the  volume  of  output  to  the  volume  of  inputs
i.e.  units  of  work  processed  per  hour).  Measurement  of
abour  input  can  therefore  be  seen  as  a  rough  estimation














































Nutritional  support  and  anti-HCV  therapy  
multiple  factors  [34].  Moreover,  similar  to  the  current  study,
most  studies  regarding  impact  of  CHC  infection  and  antiviral
therapy  on  work  impairment  used  patient  reported  instead
of  objective  measures,  which  may  introduce  measurement
error  and  bias  [15].
Results  of  the  current  study  were  validated  in  a  retro-
spective  group  of  111  CHC  patients  under  care  in  our  hospital
in  the  period  2011—2014.  In  line  with  findings  of  the  current
study,  only  half  of  patients  performed  paid  labour  at  base-
line.  Furthermore,  there  was  also  a  strong  decrease  in  paid
labour  productivity  after  24  and  48  weeks  of  PEG-interferon-
containing  antiviral  therapy  (—51%  and  —57%,  respectively).
Most  patients  in  this  group  performed  physical  exercise  at
baseline.  However,  there  was  a  dramatic  decrease  in  phys-
ical  exercise:  proportion  of  patients  without  any  physical
exercise  increased  from  14%  at  baseline  to  54%  and  77%  after
24  and  48  weeks  of  treatment,  respectively.  Although  per-
centages  slightly  differ  between  this  group  and  the  current
study,  decreases  in  paid  labour  productivity  and  physical
exercise  during  antiviral  therapy  are  large.
The  potential  underlying  mechanisms  for  the  beneficial
effects  of  nutritional  support  during  antiviral  therapy  on
paid  labour  productivity,  physical  exercise  and  performance
status  may  be  an  improved  nutritional  state  and  higher
quality  of  life,  as  demonstrated  previously  [7]. In  the  ‘‘on
demand’’  group  of  our  RCT,  there  was  a  trend  towards
a  higher  loss  of  paid  labour  productivity  after  24  weeks
of  treatment  in  those  patients  who  performed  blue  collar
labour  at  baseline  than  in  those  with  white  collar  labour
(data  not  shown).
Preventive  nutritional  support  during  antiviral  therapy
and  its  beneficial  effect  on  paid  labour  productivity  may
theoretically  be  cost-effective.  According  to  the  current
study,  nutritional  advice  and  supplementation  during  antivi-
ral  treatment  may  reduce  costs  due  to  loss  of  paid  labour
productivity  with  49%.  Based  on  an  average  income  of  28,400
euro  in  2010  in  The  Netherlands  (data  from  Central  Bureau
of  Statistics),  nutritional  advice  and  support  would  lead  to
a  reduction  in  costs  due  to  loss  of  paid  labour  productiv-
ity  of  6436  euro  per  patient  per  24  weeks  of  treatment.  On
the  other  hand,  in  the  Netherlands  total  costs  for  preven-
tive  nutritional  advice  plus  evening  supplementation  during
24  weeks  of  antiviral  therapy  are  only  approximately  660
euro  per  patient.
Paid  labour  status  is  influenced  by  multiple  factors,
such  as  patient  preference,  co-morbidity  and  age.  Indeed,
patients  with  CHC  may  have  several  comorbidities  that  limit
ability  to  work.  For  example,  IV  drug  use  is  a  common
mode  of  transmission  of  CHC  and  is  associated  with  psy-
chiatric  conditions  [35].  Furthermore,  in  the  current  study,
two  patients  had  haemophilia  and  these  patients  may  be
restricted  by  joint  problems  to  perform  blue  collar  labour.
Only  one  patient  in  the  ‘‘on  demand’’  group  and  none  in
the  preventive  group  was  ≥  65  years  of  age  and  did  not  have
paid  labour  at  baseline.
Recently,  several  new  generation  direct-acting  antivi-
rals  (DAAs)  have  been  approved.  Therefore,  interferon-free
treatment  strategies  for  CHC  are  nowadays  possible,  which
are  more  effective  and  better  tolerated  [36—39]. As  a  result,
the  role  of  interferon-containing  therapy  in  CHC  treatment
will  be  limited  in  the  future.  However,  in  specific  geo-





conomically  deprived  regions,  interferon-containing  antivi-
al  therapy  may  still  be  a  reasonable  option  due  to  excessive
osts  of  the  new  DAAs  [39].  Furthermore,  results  of  the  new
reatment  regimens  in  genotype  3-infected  patients  have
een  suboptimal  [40].
According  to  a  recent  publication  [41],  work  productiv-
ty  may  be  less  affected  by  dual  therapy  with  sofosbuvir
nd  ribavirin  than  with  triple  therapy  with  sofosbuvir,  ribavi-
in  and  PEG-interferon.  Nevertheless,  proportion  of  patients
ith  paid  labour  did  not  decrease  during  treatment  in  either
roup.  Impairment  in  work  productivity  disappeared  within
2  weeks  after  end  of  treatment,  but  recovery  took  longer
n  patients  who  received  interferon-containing  therapy  [41].
ased  on  analyses  of  four  phase  3  clinical  trials  of  sofosbuvir,
he  new  interferon-free  treatment  regimens  lead  to  only  a
inor  decrease  in  health-related  quality  of  life,  including
he  physical  component  score  [42].
Our  study  has  several  strengths  and  limitations.  Most
mportant,  this  study  revealed  the  significant  impact  of
reventive  nutritional  advice  and  support  on  paid  labour
roductivity,  physical  exercise  activity  and  performance  sta-
us  during  PEG-interferon-containing  antiviral  therapy  for
HC,  which  was  not  well  appreciated  in  the  past.  Data
as  prospectively  collected  and  patients  were  randomly
ssigned  to  the  preventive  vs.  ‘‘on  demand’’  groups.  On  the
ther  hand,  as  mentioned  above,  data  on  paid  labour  status,
hysical  exercise  and  performance  status  relied  on  patient-
eported  measures.  Finally,  dietary  advice  combined  with
ietary  supplementation  is  more  effective  in  enhancing
hort-term  weight  gain  and  in  preventing  deterioration  of
he  nutritional  status  than  dietary  advice  alone  [43].  Since
ur  preventive  group  received  both,  it  cannot  be  concluded
rom  our  data,  which  component  was  responsible  for  the
eneficial  effects.
In  conclusion,  preventive  nutritional  advice  and  support
ecreases  loss  of  paid  labour  productivity,  physical  exercise
nd  performance  status  during  PEG-interferon-containing
reatment  for  CHC.
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